2024-519495-83-00招募中2 期
A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of SAR444336 in participants with microscopic colitis in clinical remission with budesonide.
Sanofi-Aventis Recherche & Developpement24 个研究点 分布在 8 个国家目标入组 78 人开始时间: 2025年9月29日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 78
- 试验地点
- 24
- 主要终点
- Proportion of participants with sustained steroid-free clinical remission.
研究概览
简要总结
Evaluate the efficacy of SAR444336 as steroid-free therapy in participants with microscopic colitis as compared to placebo
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Participants with histologically confirmed diagnosis of microscopic colitis (including all histological sub-types).
- •Receiving budesonide therapy.
- •Documented clinical remission from 2 weeks before screening.
- •At least 1 microscopic colitis relapse in the last 8 months prior to screening that required treatment with budesonide.
- •Body mass index within the range 18 to 35 kg/m2 (inclusive) at screening visit.
- •All contraceptive methods used by participants should be consistent with local regulations regarding the methods of contraception.
排除标准
- •Significant neutrophilic/eosinophilic infiltration, crypt abscesses, granulomata, or any evidence of IBD other than microscopic colitis.
- •Excessive consumption of beverages containing xanthine bases.
- •History of solid organ transplant.
- •Active malignancy, lymphoproliferative disease, or malignancy in remission for less than 2 years, except adequately treated (cured) localized carcinoma in situ of the cervix or ductal breast, or squamous cell carcinoma, or basal cell carcinoma of the skin.
- •Have experienced any of the following within 12 months before screening: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage III or IV heart failure.
- •Participants with a history or presence of another significant illness such as renal, neurological, ophthalmological, psychiatric, endocrine, cardiovascular, gastrointestinal, hepatic disease, metabolic, pulmonary or lymphatic.
- •Live attenuated vaccines within 6 weeks of randomization and during the study.
- •Currently receiving or had treatment within 12 months prior to screening with B or T cell depleting agents.
- •At screening, have abnormal laboratory values or ECG abnormalities.
- •Participants with recent tuberculosis (TB) vaccination or positive TB test results.
- •Evidence of infectious diarrhea in the 3 months prior to randomization.
- •Other active diarrheal conditions or suspicion of drug-induced microscopic colitis at screening, or diarrhea predominant irritable bowel syndrome.
- •Any current active viral, bacterial, or fungal infection or any medically relevant infection having occurred within 3 weeks before randomization.
- •Previous bowel surgeries.
- •Planned surgery while receiving study treatment. Dental surgeries or other types of minor surgery requiring only local anesthetic are allowed.
- •Other immunologic disorder, except controlled diabetes or thyroid disorder receiving appropriate treatment.
- •Presence or history of drug hypersensitivity associated with eosinophilia in the past 6 months.
- •History or presence of alcohol or illicit drug abuse within the past 2 years.
结局指标
主要结局
Proportion of participants with sustained steroid-free clinical remission.
Proportion of participants with sustained steroid-free clinical remission.
次要结局
- Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and adverse events of special interest (AESIs).
- Incidence of study investigational medicinal product (IMP) permanent discontinuations and study withdrawals due to treatment-emergent adverse events (TEAEs).
- Plasma concentrations of SAR444336
- Incidence of treatment-emergent anti-drug antibody (ADA) against SAR444336
研究者
Clinical Sciences and Operations
Scientific
Sanofi-Aventis Recherche & Developpement
研究点 (24)
Loading locations...
相似试验
招募中
4 期
A trial to compare efficacy and tolerability of Plenvu® and Picoprep® as cleansing agents of the large bowel before colonoscopy (examination of
the bowel with a fiberoptic device)2024-518544-21-00Aalborg University Hospital400
招募中
3 期
Single-blinded randomized investigator-initiated controlled trial to assess the efficacy of colchicine to treat patients with cardiomyopathy with myocarditis (chronic inflammatory cardiomyopathy) – Trial and Registry to study the role of genotype environment interaction in Chronic myocarditis and inflammatory cardiomyopathies with ventricular pro-arrhythmic and heart failure phenotypes (PNRR-MAD-2022-12376225)2024-517945-14-00ASST Grande Ospedale Metropolitano Niguarda80
已完成
1 期
A Clinical Study of RSS0343 in Healthy SubjectsNCT07289464Reistone Biopharma Company Limited48
已完成
3 期
SAR408701 versus docetaxel in previously treated, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) positive metastatic non-squamous non-small-cell lung cancer patients2024-515101-26-00Sanofi-Aventis Recherche & Developpement1
招募中
3 期
EvAluation of the efficacy of MaaT013 as salvage theRapy in acute GVHD patiEntS with gastrointestinal involvement, refractory to ruxolitinib; a multi-center open-label phase III trial.2024-513023-17-00MaaT PHARMA, MaaT PHARMA73